Development of non-antibiotic therapeutics for Clostridium difficile infection (CDI)
Description: PROJECT NARRATIVE Each year, 3 million Americans are infected with a bacterium called Clostridium difficile (C. difficile), which causes a potentially deadly infectious diarrhea associated with inflammation of the colon and creates a $1 billion annual burden on our healthcare system. This project outlines plans to develop novel therapeutics that neutralize bacterial toxins that mediate disease pathology to eliminate symptoms and facilitate clearance while reducing long-term antibiotic pressure.
Funding type: research
Funder scheme: R56
Start date: 2017-05-01
End date: 2018-04-30
Investigator: MATTHEW BOGYO (lead)
Institution: Stanford University
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Funded outputs count: 4
Funder award ID: R56AI127455
OpenAlex ID: G7990030728
